<DOC>
	<DOCNO>NCT02474862</DOCNO>
	<brief_summary>This study randomize control trial ( RCT ) evaluate Prenatal Walking Program ( PWP ) comparison Postpartum Prep Program ( PPP ) comparison group pregnant woman experience depressive symptom . In addition assessing change depressive symptom , investigator examine key maternal outcome ( maternal functioning , pain , anxiety , stress , fatigue ) , well infant outcome include birth record data ( gestation , weight , Apgar score , etc ) careful , in-person assessment infant neurobiological function 30 day postpartum .</brief_summary>
	<brief_title>Healthy Expectations - A Program Pregnant Women Experiencing Depressive Symptoms</brief_title>
	<detailed_description>Depressive symptom prevalent among pregnant woman , consistently link adverse outcome woman infant , include high rate spontaneous abortion , preeclampsia , operative delivery , postpartum depression . Additional risk offspring include pre-term delivery , neonatal growth retardation , low birth weight , delay developmental milestone . In spite risk , vast majority affect woman pursue type mental health treatment . Many woman reluctant use antidepressant - anything could potentially harm baby - prenatally . Because pregnant woman unique concern regard treatment acceptability , critical need exists develop intervention efficacious reduce depressive symptom , also view acceptable pregnant woman . Increased physical activity numerous advantage strategy improve mood pregnancy , prior research show physical activity intervention effective treat depressive symptom general population . Physical activity intervention also inexpensive , safe , associated variety positive health outcome . In spite potential acceptable efficacious strategy improve prenatal mood , study evaluate physical activity intervention pregnant woman depressive symptom . Existing exercise program test reduce depressive symptom general population likely appropriate feasible pregnant woman . In light important gap , investigator interdisciplinary team develop gentle , 10-week , pedometer walk intervention tailor pregnant woman , Prenatal Walking Program ( PWP ) preliminarily evaluate PWP open trial , find intervention safe , feasible , acceptable . The current RCT evaluate PWP comparison health education control comparison group tailor perinatal woman , call Postpartum Prep Program ( PPP ) . In addition assessing change depressive symptom , investigator examine key maternal outcome ( maternal functioning , pain , anxiety , stress , fatigue ) , well infant outcome include birth record data in-person assessment infant neurobiological functioning . Further , investigator examine evidence potential behavioral , psychological , biological mechanism action mediate possible treatment effect . Up 152 pregnant woman report elevated depressive symptom current pregnancy enrol randomized one two group , PWP PPP , participate blind follow-up evaluation multiple time-points throughout pregnancy postpartum .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<criteria>1. woman age 18 2 . 1226 week gestation healthy singleton pregnancy 3 . Englishspeaking 4. cleared prenatal provider moderate intensity exercise 5. experience moderate depressive symptom elevation time enrollment ( QIDSC ; 920 ) ; ( 6 ) physically inactive lowactive time enrollment ( mean &lt; 90 minutes/week moderate intensity exercise , last 3 month ) . 1. recently start pharmacologic psychosocial treatment depressive symptom within past 4 week , recently change dose treatment regimen past 4 week 2. current/recent acute suicidal symptoms 3. current substance use disorder 4. psychotic symptom cognitive impairment 5. current eat disorder 6. current lifetime bipolar disorder , schizophrenia , schizoaffective disorder . Finally , follow exclude participant enrollment study , woman meet two criterion exclude participate blood draw component examine inflammatory marker : 7. current significant physical neurological illness , ie. , acute chronic infectious , inflammatory immune disorder 8. regular use aspirin nonsteroidal antiinflammatory drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>